APC/Cyanine7 anti-mouse CD4 Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

Mouse CTL clone V4

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.

Concentration

0.2 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is =1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser

Red Laser (633 nm)

Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4⁺ T cell activation^1,4,11, thymocyte costimulation³, in vitro and in vivo depletion^2,5-8, blocking of egg-sperm cell adhesion^1,4, immunohistochemical staining of acetone-fixed frozen sections^9,10, immunoprecipitation^1,2, and spatial biology (IBEX)^12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Additional Product Notes

BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact Technical Service if you have any questions.

Application References

(PubMed link indicates BioLegend citation)

1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed

Product Citations

1. Strickley JD, et al. 2019. Nature. 575:519. PubMed
2. Vasanthakumar A, et al. 2020. Nature. 579:581. PubMed
3. Bergot AS, et al. 2020. J Immunol. 204:1787. PubMed
4. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
5. Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed
6. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
7. Li H, et al. 2022. Cell Rep Med. 3:100554. PubMed
8. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
9. Fan L, et al. 2021. Cancers (Basel). 13:. PubMed
10. Boyd DF, et al. 2020. Nature. 587:466. PubMed
11. Shao B, et al. 2018. Mol Med Rep. 18:920. PubMed
12. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
13. Aldon Y, et al. 2020. J Immunol. 204:903. PubMed
14. Pandey S, et al. 2020. Cell Syst. 11:495. PubMed
15. Chen J, et al. 2021. Sci Adv. 7:. PubMed
16. Dong L, et al. 2021. Cancer Cell. . PubMed
17. Andreas N, et al. 2021. Arthritis Res Ther. 23:222. PubMed
18. Wang Q, et al. 2020. Wound Repair Regen. 28:105. PubMed
19. Saito S, et al. 2020. Nutrients. 12:. PubMed
20. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
21. Petursdottir D, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01699. PubMed
22. Pérez‐Mazliah D et al. 2017. EBioMedicine. 24:216-230 . PubMed
23. Treger RS, et al. 2020. Immunity. 50(2):334-347.e9.. PubMed
24. Inoue D, et al. 2021. Nat Genet. 53:707. PubMed
25. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
26. Lutes LK, et al. 2021. eLife. 10:00. PubMed
27. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
28. Markov SD, et al. 2021. Mol Cancer Ther. 20:2457. PubMed
29. Ontiveros-Padilla L, et al. 2021. Microorganisms. 9:. PubMed
30. Ciarlo E, et al. 2016. Sci Rep. 6:37944. PubMed
31. Kunimoto H, et al. 2018. Cancer Cell. 33:44. PubMed
32. Yu X, et al. 2022. J Extracell Vesicles. 11:e12185. PubMed
33. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
34. Feng H, et al. 2020. J Dermatol. 47:147. PubMed
35. Mizraji* G, et al. 2013. J Vis Exp. 77: 50388. PubMed
36. Collinson-Pautz M, et al. 2016. PLoS One. 11:e0164547. PubMed
37. Chun E, et al. 2020. Immunity. 51(5):871-884.e6.. PubMed
38. Wang GZ, et al. 2019. Nat Commun. 10:1125. PubMed
39. Kleppe M et al. 2018. Cancer cell. 33(1):29-43 . PubMed
40. Levescot A, et al. 2021. J Clin Invest. 131:. PubMed
41. Levi J, et al. 2020. J Nucl Med. . PubMed
42. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
43. Holvoet B, et al. 2015. Stem Cell Reports. 5: 1183-1195. PubMed
44. Ma W, et al. 2017. Sci Rep. . 10.1038/s41598-017-15661-6. PubMed
45. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
46. Shi R, et al. 2022. Theranostics. 12:875. PubMed
47. Venturutti L, et al. 2020. Cell. 182(2):297-316.e27. PubMed
48. St Clair JB, et al. 2017. PLoS One. 12:e0170556. PubMed
49. Wennerberg E, et al. 2022. Sci Transl Med. 14:eabe8195. PubMed
50. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
51. Mara AB, et al. 2022. NPJ Vaccines. 7:86. PubMed
52. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
53. Zhang L, et al. 2021. Clin Transl Med. 11:e464. PubMed
54. Gary E, et al. 2020. Vaccine. 3821:38. PubMed
55. Zhang C, et al. 2020. Cell Rep. 32:108206. PubMed
56. Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed
57. Kräutler NJ, et al. 2020. Cell Reports. 30(4):997-1012.e6.. PubMed
58. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
59. Jorapur A, et al. 2022. PLoS Pathog. 18:e1010200. PubMed
60. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
61. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
62. Pham D, et al. 2019. Cell Rep. 29:1203. PubMed
63. Brown SM et al. 2017. Endocrinology. 158(10):3592-3604 . PubMed
64. Sydney Lavoie et al. 2019. eLife. 8 pii: e39982. PubMed
65. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
66. Yang S, et al. 2022. J Exp Med. 219:. PubMed
67. Ding P, et al. 2022. Bone Res. 10:42. PubMed
68. Lee L, et al. 2016. PLoS One. 11:e0167693. PubMed
69. Merlo LM, et al. 2020. Clin Pathol. 13:2632010X20951812. PubMed
70. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
71. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
72. Perry JL, et al. 2020. ACS Nano. 5.583333333. PubMed
73. Sadik A, et al. 2020. Cell. 1252:182. PubMed
74. Yeung F, et al. 2020. Cell Host & Microbe. 27(5):809-822. PubMed
75. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
76. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
77. Li M, et al. 2021. Cancers (Basel). 13:. PubMed
78. Dong X, et al. 2022. Front Immunol. 13:896472. PubMed
79. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
80. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
81. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
82. Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed
83. Zhao N, et al. 2018. J Clin Invest. 26:84. PubMed
84. Wang X, et al. 2021. Cell. 184:5357. PubMed
85. Molina MS, et al. 2021. Front Immunol. 12:699128. PubMed
86. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
87. McNamee E, et al. 2013. Gut. 62:53. PubMed
88. Porrello A, et al. 2018. Nat Commun. 9:1988. PubMed
89. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
90. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
91. Le QV, et al. 2022. Bioact Mater. 15:160. PubMed
92. Jeon Y, et al. 2015. PLoS One. 10: e0139845. PubMed
93. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
94. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
95. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
96. Luo H, et al. 2019. Cell Rep. 26:945. PubMed
97. Tippimanchai DD, et al. 2018. Oncoimmunology. 7:e1438105. PubMed
98. Chen B, et al. 2021. Cell. 184:6262. PubMed
99. Wang X, et al. 2022. Elife. 11:. PubMed
100. Ma C, et al. 2021. J Exp Med. :218. PubMed
101. Wang M, et al. 2021. iScience. 24(7):102766. PubMed
102. Sheng J, et al. 2021. eLife. 10:00. PubMed
103. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
104. Young JS, et al. 2018. Front Immunol. 9:1385. PubMed
105. Li A, et al. 2018. Cancer Lett. 431:54. PubMed
106. Liu A, et al. 2022. Front Cell Infect Microbiol. 12:960208. PubMed
107. Sen D, et al. 2016. PLoS One. 11:e0165064. PubMed
108. Ma C, et al. 2020. Sci Adv. 6:eaaz6717. PubMed
109. Wolf Y, et al. 2019. Cell. 179:219. PubMed
110. Ershaid N, et al. 2019. Nat Commun. 10:4375. PubMed
111. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
112. Liang Z, et al. 2022. iScience. 25:105233. PubMed
113. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
114. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
115. Dai B, et al. 2021. Cell Reports Medicine. 2(8):100381. PubMed
116. Xiang W, et al. 2020. Signal Transduct Target Ther. 0.374305556. PubMed

RRID

AB_312698 (BioLegend Cat. No. 100413)
AB_312699 (BioLegend Cat. No. 100414)

Antigen Details

Structure

Ig superfamily, 55 kD

Distribution

Majority of thymocytes, T cell subset

Function

TCR co-receptor, T cell activation

Ligand/Receptor

MHC class II molecule

Cell Type

Dendritic cells, T cells, Thymocytes, Tregs

Biology Area

Immunology

Molecular Family

CD Molecules

Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID

12504 View all products for this Gene ID

UniProt

View information about CD4 on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.

TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

Certificate of Analysis